End-of-life (EOL) pharmacology requires the NP to shift from a curative treatment paradigm to one focused exclusively on symptom relief and comfort. The core symptoms requiring pharmacological management in dying patients are pain, dyspnea, respiratory secretions (death rattle), nausea/vomiting, terminal restlessness/agitation, and seizures. Several pharmacological principles differ fundamentally from standard prescribing: (1) Route of administration: as patients lose the ability to swallow, the NP must transition medications to alternative routes -- subcutaneous (preferred for most EOL medications because it avoids the need for IV access), sublingual/buccal (morphine concentrated solution, lorazepam, atropine drops), rectal (acetaminophen, diazepam, morphine), and transdermal (fentanyl patches for stable opioid requirements); the oral route becomes unreliable and eventually impossible. (2) Goal of therapy shifts from titrating to a lab value or clinical parameter to titrating to COMFORT -- the endpoint is symptom relief, not a target vital sign or level. (3) The principle of double effect provides ethical and legal justification for EOL prescribing: administering opioids or sedatives with the PRIMARY intent of relieving suffering is ethically appropriate even if a SECONDARY effect may be hastening death;...